Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Battaglia

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Frontiers in Immunology|May 24, 2021
IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells <i>via</i> Aryl Hydrocarbon Receptor ActivationAdaobi Amobi-McCloud, Ravikumar Muthuswamy, Sebastiano Battaglia, et al.
Nature Communications|March 4, 2021
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitorsTakayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, et al.
Science Advances|December 6, 2023
Innate TCRβ-chain engagement drives human T cells toward distinct memory-like effector phenotypes with immunotherapeutic potentialsPierre Vantourout, Josephine Eum, María Conde Poole, et al.
Oncotarget|July 18, 2020
Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancerTakemasa Tsuji, Kevin H Eng, Junko Matsuzaki, et al.
Plos Genetics|February 16, 2018
Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry studyKevin H Eng, J Brian Szender, John Lewis Etter, et al.
International Journal of Cancer|July 3, 2019
Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genesQianqian Zhu, Jianmin Zhang, Yanmin Chen, et al.
Nature Communications|December 5, 2024
Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancerSpencer R Rosario, Mark D Long, Shanmuga Chilakapati, et al.
Carcinogenesis|May 15, 2010
Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesionSebastiano Battaglia, Orla Maguire, James L Thorne, et al.
Journal for Immunotherapy of Cancer|June 22, 2019
Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancerSong Liu, Junko Matsuzaki, Lei Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2025
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker ResultsAndrea Necchi, Félix Guerrero-Ramos, Paul L Crispen, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Frontiers in Immunology|May 24, 2021
IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells <i>via</i> Aryl Hydrocarbon Receptor ActivationAdaobi Amobi-McCloud, Ravikumar Muthuswamy, Sebastiano Battaglia, et al.
Nature Communications|March 4, 2021
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitorsTakayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, et al.
Science Advances|December 6, 2023
Innate TCRβ-chain engagement drives human T cells toward distinct memory-like effector phenotypes with immunotherapeutic potentialsPierre Vantourout, Josephine Eum, María Conde Poole, et al.
Oncotarget|July 18, 2020
Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancerTakemasa Tsuji, Kevin H Eng, Junko Matsuzaki, et al.
Plos Genetics|February 16, 2018
Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry studyKevin H Eng, J Brian Szender, John Lewis Etter, et al.
International Journal of Cancer|July 3, 2019
Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genesQianqian Zhu, Jianmin Zhang, Yanmin Chen, et al.
Nature Communications|December 5, 2024
Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancerSpencer R Rosario, Mark D Long, Shanmuga Chilakapati, et al.
Carcinogenesis|May 15, 2010
Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesionSebastiano Battaglia, Orla Maguire, James L Thorne, et al.
Journal for Immunotherapy of Cancer|June 22, 2019
Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancerSong Liu, Junko Matsuzaki, Lei Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2025
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker ResultsAndrea Necchi, Félix Guerrero-Ramos, Paul L Crispen, et al.
Pageof 5